Chamberlain will be heading up a number of client accounts including Roche's growing rheumatoid arthritis portfolio and Boehringer-Ingelheim's anticoagulant Pradaxa. His appointment increases the agency to 13 staff.
‘Mark joining Reynolds-MacKenzie is another significant development for us,' said Reynolds-MacKenzie co-founder and director Alison MacKenzie. ‘He will be responsible for leading on several important pieces of business, providing additional senior level support and allowing the agency to grow even further. His experience in the strategic planning, management and tactical delivery of a range of programmes will prove invaluable.'
Chamberlain has over eight years of experience in healthcare PR, in both permanent and freelance positions. He has led both consumer and medical PR programmes for varying UK and international clients, working on a number of high profile launches and campaigns.
Reynolds-MacKenzie was founded in 2004 by directors Eva Reynolds and Alison MacKenzie.